- Home
- PCVX vs VNO Comparison
PCVX vs VNO Comparison
Compare PCVX & VNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | VNO |
|---|---|---|
| Founded | 2013 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.1B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PCVX | VNO |
|---|---|---|
| Price | $54.00 | $26.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 10 |
| Target Price | ★ $98.33 | $36.00 |
| AVG Volume (30 Days) | 1.0M | ★ 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.84% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.50 |
| P/E Ratio | ★ N/A | $7.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.09 | $25.28 |
| 52 Week High | $76.61 | $43.37 |
Technical Indicators
Market Signals| Indicator | PCVX | VNO |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 33.18 |
| Support Level | $42.30 | $25.71 |
| Resistance Level | $57.50 | $32.81 |
| Average True Range (ATR) | 3.05 | 1.04 |
| MACD | -0.94 | -0.09 |
| Stochastic Oscillator | 1.39 | 19.01 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.